CLINICAL TRIALS PROFILE FOR PRAMIPEXOLE DIHYDROCHLORIDE

All Clinical Trials for PRAMIPEXOLE DIHYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00025792 ↗	Clinical Trial of Pramipexole in Bipolar Depression	Completed	National Institute of Mental Health (NIMH)	Phase 2	2001-10-01	The purpose of this study is to examine the safety and effectiveness of the drug pramipexole given in combination with lithium or divalproex for the short-term treatment of acute depression in patients with bipolar disorder. Bipolar disorder is a severe, chronic, and often life-threatening illness. Treatments for acute unipolar depression have been extensively researched. However, despite the availability of a wide range of antidepressant drugs, a significant proportion of depressed patients fail to respond to first-line antidepressant treatment. Novel and improved therapeutics for bipolar depression are needed. This study will evaluate the antidepressant properties of pramipexole. This study will be conducted in three phases. Phase 1 is a 14-day washout period in which participants will be tapered off all their psychiatric medicines except divalproex or lithium. Participants will also be asked to adhere to a low caffeine and low monoamine diet. During Phase 2, participants will be randomly assigned to receive either pramipexole or placebo (an inactive pill) for 6 weeks. Participants who respond to treatment will be given either open-label pramipexole or another clinical treatment. Participants will be screened with a medical history, physical examination, electrocardiogram (EKG), blood and urine tests, and a psychiatric evaluation. Women of childbearing potential will have a pregnancy test. Participants will have a physical exam and EKG at study entry and study completion. Blood will be drawn at various times throughout the study. Pulse and blood pressure measurements will be taken daily. Weekly interviews will be conducted. Participants and a control group of healthy volunteers will undergo positron emission tomography (PET) and magnetic resonance imaging (MRI) scans of the brain.
NCT00086294 ↗	ACP-103 to Treat Parkinson's Disease	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	2004-06-25	This study will evaluate the effects of an experimental drug called ACP-103 on Parkinson's disease symptoms and on dyskinesias (involuntary movements) that develop as a result of long-term levodopa treatment. ACP-103 changes the spread of certain brain signals that are affected in patients with Parkinson's disease. Patients with relatively advanced Parkinson's disease and dyskinesias who are between 30 and 80 years of age may be eligible for this study. Candidates are screened with a complete medical history and physical examination, neurological evaluation, blood and urine tests, and electrocardiogram (ECG). A brain magnetic resonance imaging (MRI) scan, CT scan, and chest x-ray may be done if medically indicated. Patients enrolled in the study will, if possible, stop taking all antiparkinsonian medications for one month (2 months for Selegiline) before the study begins and throughout its duration. Exceptions are Sinemet (levodopa/carbidopa), Mirapex (pramipexole) and Requip (ropinirole). Levodopa Dose Finding After the screening evaluations, patients are admitted to the NIH Clinical Center for 2 to 3 days to undergo a levodopa "dose-finding" procedure. For this test, patients stop taking Sinemet and instead have levodopa infused through a vein. During the infusion, the drug dose is increased slowly until either 1) parkinsonian symptoms improve, 2) unacceptable side effects occur, or 3) the maximum study dose is reached. Side effects are monitored closely during the infusions, and parkinsonian symptoms are evaluated frequently during and after the infusions. The infusions usually begin early in the morning and continue until evening. Once the infusion is finished, patients resume taking their regular oral Sinemet dose. The infusions are repeated once a week during 1-day inpatient evaluations. Treatment Patients are randomly assigned to take either ACP-103 followed by placebo (a look-alike pill with no active ingredient) once a week for 10 weeks or vice versa (placebo followed by ACP-103). Patients are admitted to the Clinical Center for each dose. During this admission they have a brief medical examination, blood and urine tests, ECG, and review of symptoms or changes in their condition. They also have an infusion of levodopa (see above) at the previously determined optimal rate. Parkinsonism symptoms and dyskinesias are evaluated every 30 minutes for about 6 hours. At the end of the infusions and ratings, patients are discharged home with their regular Parkinson's medications until the following visit. Two weeks after their final dose of ACP-103 or placebo, patients are contact by telephone for a follow-up safety check. At that time, the investigator may ask the patient to return to the clinic for closer evaluation.
NCT00086307 ↗	Lexapro and Pramipexole and to Treat Major Depression	Completed	National Institute of Mental Health (NIMH)	Phase 2	2004-06-01	This study compares the effectiveness of the combination of antidepressants: Lexapro and Pramipexole, with the effectiveness of each antidepressant alone. Purpose: Patients between 18 and 65 years of age with Major Depressive Disorder without psychotic features may be eligible for this 9-week study. Candidates must currently be in a major depressive episode of at least 4 weeks' duration, have failed to respond to treatment with an SSRI (Prozac, Zoloft, Paxil, Luvox, Celexa), and not have failed to respond to more than four antidepressants for the current episode. Candidates are screened with a physical examination, psychiatric evaluation, blood tests, review of vital signs, height and weight measurements, electrocardiogram (ECG), urine test for illegal drugs, and pregnancy test for women. Participants are tapered off antidepressants or other medications prohibited during the study and remain drug-free for 1 week before starting treatment. They are then randomly assigned to take pramipexole and escitalopram, pramipexole alone, or escitalopram alone for 6 weeks. During the study, participants come to the clinic eight times for health assessments and symptoms assessments, which include a check of vital signs and rating scales for depression and anxiety, adverse events, and sexual functioning. Blood and urine samples are collected periodically to monitor health, detect pregnancy in women, and detect illicit drug use. At the end of the 6-week treatment period, participants have a physical examination, ECG, blood test, and check of vital signs. Short-term anti-depressant treatment is offered, and plans are made for long-term treatment. Atendemos pacientes de habla hispana. ...
NCT00096720 ↗	Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease	Completed	Boehringer Ingelheim	Phase 2	2004-02-01	Study participants who have been clinically diagnosed with Parkinson disease will receive no treatment, treatment with either levodopa, or treatment with Mirapex for a period of 12 weeks. Over the course of the study subjects will travel to the Institute for Neurodegenerative Disorders (IND) in New Haven, Connecticut for brain imaging.
NCT00096720 ↗	Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease	Completed	United States Department of Defense	Phase 2	2004-02-01	Study participants who have been clinically diagnosed with Parkinson disease will receive no treatment, treatment with either levodopa, or treatment with Mirapex for a period of 12 weeks. Over the course of the study subjects will travel to the Institute for Neurodegenerative Disorders (IND) in New Haven, Connecticut for brain imaging.
NCT00096720 ↗	Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease	Completed	Institute for Neurodegenerative Disorders	Phase 2	2004-02-01	Study participants who have been clinically diagnosed with Parkinson disease will receive no treatment, treatment with either levodopa, or treatment with Mirapex for a period of 12 weeks. Over the course of the study subjects will travel to the Institute for Neurodegenerative Disorders (IND) in New Haven, Connecticut for brain imaging.
NCT00102856 ↗	Neuromodulation and Language Acquisition (Stage Ib)	Suspended	University Hospital Muenster	Phase 4	2005-01-01	The purpose of this study is to determine whether rivastigmine or pramipexol are effective in boosting semantic language acquisition in healthy subjects.

Clinical Trial Conditions for PRAMIPEXOLE DIHYDROCHLORIDE

Condition Name

Condition Name for PRAMIPEXOLE DIHYDROCHLORIDE
Intervention	Trials
Parkinson Disease	36
Restless Legs Syndrome	24
Healthy	11
Depression	10

Condition MeSH

Condition MeSH for PRAMIPEXOLE DIHYDROCHLORIDE
Intervention	Trials
Parkinson Disease	53
Restless Legs Syndrome	25
Psychomotor Agitation	24
Syndrome	23

Clinical Trial Locations for PRAMIPEXOLE DIHYDROCHLORIDE

Trials by Country

Trials by Country for PRAMIPEXOLE DIHYDROCHLORIDE
Location	Trials
United States	325
Germany	34
Spain	14
United Kingdom	11
Austria	11

Trials by US State

Trials by US State for PRAMIPEXOLE DIHYDROCHLORIDE
Location	Trials
New York	21
California	21
Massachusetts	19
Florida	17
Georgia	16

Clinical Trial Progress for PRAMIPEXOLE DIHYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for PRAMIPEXOLE DIHYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	4
Phase 4	28

Clinical Trial Status

Clinical Trial Status for PRAMIPEXOLE DIHYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	90
RECRUITING	7
Unknown status	7

Clinical Trial Sponsors for PRAMIPEXOLE DIHYDROCHLORIDE

Sponsor Name

Sponsor Name for PRAMIPEXOLE DIHYDROCHLORIDE
Sponsor	Trials
Boehringer Ingelheim	57
National Institute of Mental Health (NIMH)	8
Region Skane	3

Sponsor Type

Sponsor Type for PRAMIPEXOLE DIHYDROCHLORIDE
Sponsor	Trials
Industry	85
Other	82
NIH	11

Pramipexole Dihydrochloride: Clinical Trials Update, Market Analysis, and 2025-2035 Projection

Last updated: April 27, 2026

What is pramipexole dihydrochloride and where is it used?

Pramipexole dihydrochloride is a dopamine receptor agonist used for:

• Parkinson’s disease (PD): symptomatic treatment, including early and advanced disease (often as monotherapy or adjunct).
• Restless legs syndrome (RLS): symptomatic treatment.

It is marketed as an established generic and also under branded formats in prior cycles. Patent protection across geographies has largely expired, so market outcomes are dominated by generic competition, payer positioning, and formulary access rather than new originator innovation.

---

What does the current clinical-trials landscape show?

No single consolidated “active development” pipeline can be stated from the provided prompt. The clinical-trials update below therefore focuses on how pramipexole continues to appear in registries: trials typically address one or more of the following study designs:

• Formulation and bioequivalence (including IR vs ER dosing comparisons)
• Drug repositioning or comparative effectiveness against other RLS/PD agents
• Symptom subtyping (sleep, circadian symptoms, mood-related endpoints in PD; sensory and sleep endpoints in RLS)
• Real-world evidence follow-ons for tolerability and discontinuation patterns

Practical implication for R&D and investment screens: For pramipexole, the highest-likelihood incremental clinical activity is supportive development (bioequivalence, population-specific studies, adherence and tolerability studies) rather than disease-modifying mechanisms. That keeps probability-weighted returns tied to regulatory strategy and manufacturing cost, not blockbuster differentiation.

---

How does the market price-and-volume structure behave for pramipexole?

Market outcomes for pramipexole are shaped by three forces:

1) Generic substitution has structural price pressure

• Once multiple generic competitors establish supply, gross-to-net declines and wholesale pricing compress.
• Expect low single-digit to mid single-digit annual net sales growth at most, unless a new branded or specialty pathway creates premium pricing.

2) Therapy switching is limited by established prescribing patterns

• In PD and RLS, neurologists and sleep-medicine prescribers often maintain stable dopamine agonist regimens if patients tolerate them.
• This supports baseline demand even as pricing declines.

3) Safety monitoring influences persistence

Dopamine agonists carry class-specific risks (notably impulse control disorders and sleep-related adverse events in RLS/PD treatment frameworks). These risks drive:

• Tighter patient selection
• Periodic dose adjustments
• Higher discontinuation rates in high-risk subgroups
• Formulary scrutiny in some payers

Net effect: The market is usually resilient on volume but constrained on margin.

---

What is the likely market size and dynamics (2025 baseline)?

A reliable projection requires a baseline revenue figure by geography and segment. The prompt provides none, so an evidence-backed number cannot be produced without fabricating data.

Actionable approach for business planning without baseline inflation:

• Model pramipexole demand as (1) prevalent patient population × (2) persistence rate × (3) average daily dose × (4) net price after rebates.
• Use scenario ranges for net price erosion and volume stability:
  • If generic entrants continue, assume additional net price erosion.
  • If competitive dynamics slow, net price erosion may flatten but will not reverse absent specialty repricing.

Given the typical class pattern post-generic entry, the most consistent assumption is:

• Volume: stable to slightly down (aging and competition may reduce share)
• Net price: downward
• Net sales: flat to modest decline in many markets unless ER formulations or RLS guideline updates temporarily support share retention.

---

Where do the strongest commercial levers sit?

Commercial upside for an established molecule is usually tied to operational rather than clinical innovation:

1) Formulation and dosing advantage

If a payer prefers lower dosing frequency, ER versions can sustain share. In PD, titration schedules and tolerability drive preference.

2) Formulary placement and rebate strategy

• Dominant lever for generics is rebate positioning
• Secondary lever is package size and channel coverage (retail vs mail-order)

3) Adherence and patient persistence programs

Because discontinuation and dose changes are common in dopamine agonist therapy, adherence support can stabilize volume.

4) Geography mix

Markets with slower generic penetration keep prices higher longer. Markets with rapid tendering and reference pricing compress margins faster.

---

2025-2035 projection: what direction is most likely for net sales?

Because no baseline market size is provided in the prompt, only directional projections with drivers can be stated without inventing numbers.

Base case (most probable): flat-to-declining net sales

• Net price declines continue due to generic competition.
• Volume stays near steady due to persistent use in PD/RLS.
• Result: modest decline or flat performance, with volatility by geography.

Bear case: faster net sales contraction

• Additional generic entrants or aggressive tendering.
• Payer restrictions in higher-risk subgroups.
• Increased substitution to alternatives with better payer terms or perceived tolerability.

Bull case: modest stabilization or low growth

• Competitive pricing stabilizes after consolidation.
• ER/formulation share gains in RLS or PD symptom clusters.
• Strong persistence via adherence programs and stable physician practice patterns.

---

What should an investor or R&D decision maker underwrite?

Pramipexole is best underwritten as a manufacturing-and-access business, not a late-stage innovation asset. Decision variables:

• Cost position: API and tablet costs, yield, and supply reliability.
• Regulatory execution: bioequivalence and line extensions (if used to defend formulations and package portfolios).
• Payer contracting: rebate structure and tender compliance.
• Portfolio role: whether pramipexole is a base franchise product used to maintain channel access for a larger neurology generic line.

Investment bottom line: Expected returns are tied to defending share and margin against generics, not to breakthrough trial readouts.

---

Key risks that typically move the economics

• Further price erosion from additional suppliers or more aggressive reference pricing
• Guideline shifts that reduce dopamine agonist share (RLS sequencing, PD symptom management preferences)
• Safety signaling leading to tighter prescribing controls or payer edits
• Supply disruptions or quality events affecting continuity of supply
• Switching friction: even when alternatives win on price, prescribers may delay switches for stable patients, which can also cut both ways

---

Key Takeaways

• Pramipexole dihydrochloride is a well-established dopamine agonist for PD and RLS with clinical development that is typically supportive (formulation, comparative, or population-specific studies).
• Market performance is dominated by generic substitution, payer contracting, and persistence, not by new patent-protected differentiation.
• Without a provided baseline, the most defensible 2025-2035 outlook is flat-to-declining net sales in many markets, driven by net price erosion offset partly by volume resilience.
• The highest-leverage commercial actions are cost position, tender/rebate strategy, and formulation share defense (including ER if it holds payer preference).

---

FAQs

1) Is pramipexole expected to generate major revenue growth from new clinical outcomes?

No. For an off-patent dopamine agonist, clinical value tends to support labeling, formulation, or comparative use rather than create pricing power.

2) What most strongly determines pramipexole generic profitability?

Net price after rebates and supply cost. Share can be stable, but margins compress as competition intensifies.

3) How do PD and RLS indications affect demand stability?

Both indications support baseline use. PD tends to be more persistence-driven; RLS can be more sensitive to payer guidance and treatment sequencing.

4) Do safety considerations materially change payer behavior?

Often. Class-specific adverse-event considerations can drive patient selection edits and affect discontinuation and therefore volume.

5) What is the most realistic upside path for a manufacturer?

Defend formulary access through rebate strategy, maintain cost leadership, and protect formulation and package positions (IR vs ER) that match prescriber and payer preferences.

---

References

[1] U.S. FDA. “Pramipexole” (drug label information and pharmacology context). https://www.accessdata.fda.gov/
[2] European Medicines Agency (EMA). “Pramipexole” product information (where applicable). https://www.ema.europa.eu/
[3] ClinicalTrials.gov. Search results for “pramipexole” (trial listings, formats, and study types). https://clinicaltrials.gov/